Skip to content
HowShorted

CAPRICOR THERAPEUTICS, INC. short interest in 2023

In 2023, CAPRICOR THERAPEUTICS, INC.'s disclosed short interest ran from 1.36% of shares outstanding on 13 Jan 2023 to 7.64% on 29 Dec 2023, a change of +6.28 percentage points. The year's high was 7.64% on 29 Dec 2023 and its low 1.01% on 31 May 2023, averaging 2.37% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.50 days on 30 Nov 2023. Full history: CAPRICOR THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CAPRICOR THERAPEUTICS, INC. in 2023

2023 in figures

Start of year
1.36% (13 Jan 2023)
End of year
7.64% (29 Dec 2023)
Change
+6.28 pp
High
7.64% (29 Dec 2023)
Low
1.01% (31 May 2023)
Average
2.37%
Highest days to cover
10.50 (30 Nov 2023)
SEC filings marked
8

Every report in 2023

CAPRICOR THERAPEUTICS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20231.36%3.79
31 Jan 20231.30%2.20
15 Feb 20231.23%5.02
28 Feb 20231.34%3.13
15 Mar 20231.40%3.24results (8-K)
31 Mar 20231.09%3.7410-K filed
14 Apr 20231.05%4.70
28 Apr 20231.05%3.94
15 May 20231.17%6.25results (8-K), 10-Q filed
31 May 20231.01%3.84
15 Jun 20231.02%3.14
30 Jun 20231.09%2.11
14 Jul 20231.09%6.78
31 Jul 20231.10%7.96
15 Aug 20231.22%1.78results (8-K), 10-Q filed
31 Aug 20231.56%1.64
15 Sep 20232.12%4.42
29 Sep 20232.60%1.84
13 Oct 20234.69%2.84
31 Oct 20234.78%6.27
15 Nov 20234.43%6.7610-Q filed, results (8-K)
30 Nov 20234.75%10.50
15 Dec 20236.90%6.23
29 Dec 20237.64%8.17

See also: CAPRICOR THERAPEUTICS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.